Ionis

News

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.

News

Roche has scrapped two drugs for Huntington's disease – tominersen and RG6496 – after seeing disappointing results in clinical trials.

News

Prospects for AstraZeneca and Ionis' Wainua have been severely dented by a failed trial in ATTR cardiomyopathy, weighing on the shares of both firms.

News

An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.

News

Ionis gets FDA nod for its HAE attack prophylactic treatment Dawnzera, offering less frequent dosing than its rivals.

News

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.